Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company developing T-cell therapies for blood cancers and solid tumors. Its lead program, EB103, is an ARTEMIS®-based CD19-targeted T-cell therapy in Phase I/II testing, while EB104 and related combination work remain in early development.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueEB103 is the company's lead CD19-targeted T-cell therapy advancing through Phase I/II testing.
EB104 and other preclinical/early-stage T-cell therapy efforts targeting CD22 and related indications.
Work with Imugene and Eureka on combination approaches such as CF33-CD19t with EB103.
Trial execution, IND-enabling work, and outsourced development services supporting the pipeline.
Customers
Estrella does not yet sell commercial products; its current 'customers' are effectively patients, investigators, clinical sites, and regulators involved in advancing its therapies. In the future, if approved, its therapies would be used by oncology treatment centers and prescribed by physicians for patients with hematologic cancers and potentially solid tumors.
Patients enrolled in STARLIGHT-1 and related studies receive the investigational therapy to generate safety and efficacy data.
Hospitals and cancer centers would be the channel for commercial use if EB103 or EB104 reach approval.
Specialist clinicians select patients, run trials, and influence adoption of cell therapy protocols.
The FDA and similar agencies review INDs and marketing applications that determine whether programs can proceed.
Eureka and Imugene support platform access, services, and combination-development work.
Strategy
Estrella's strategy is to advance its ARTEMIS®-licensed T-cell platform through clinical proof-of-concept, starting with EB103 and supported by EB104 and combination research. The company is also building the organizational and capital structure needed to fund development, manage public-company obligations, and preserve optionality for future commercialization or partnering.
Clinical data are the main value driver for a pre-revenue cell therapy company and are needed for regulatory progress.
A second asset and combination programs reduce single-asset risk and broaden the platform's commercial potential.
The company has no product revenue and depends on external capital to finance trials and corporate overhead.
Geography
Estrella is headquartered in the United States and its development activity is centered around U.S. regulatory and clinical infrastructure. The company also established a wholly owned subsidiary in Hong Kong in late 2024, indicating a broader Asia-linked operating footprint, but it has not disclosed revenue geography because it has not generated revenue.
Risks
Estrella is a pre-revenue biotech, so its business depends on successful clinical development, regulatory approval, and continued access to capital. The company also faces public-market and execution risks, including Nasdaq listing compliance, reliance on related-party services, and the possibility that its therapies never reach commercialization.
- Nasdaq listing complianceImpact: HighLikelihood: Medium
The company received a bid-price deficiency notice, and delisting would hurt liquidity and capital-raising ability.
Exposure: Common stock trading on Nasdaq Capital Market
- Financing riskImpact: HighLikelihood: Low
The company has no product revenue and expects to fund operations through external capital, which may be unavailable or dilutive.
Exposure - Clinical development failure or delayImpact: High
EB103 and EB104 are still in early-stage testing, so safety, efficacy, enrollment, or manufacturing issues could prevent approval.
Exposure: STARLIGHT-1 and future pipeline programs
- Regulatory approval riskImpact: High
Even promising data may not translate into approval, and the company cannot monetize until regulators clear its products.
Exposure: FDA IND and future marketing applications
- Related-party dependenceImpact: Medium
Eureka performs key development services and owns the underlying platform license, creating concentration and negotiation risk.
Exposure: Clinical trial execution and technology access
Accounting
Judgemental itemsThe company has not generated revenue, so future recognition will depend on approval and commercialization timing.
Impact: No current sales; future revenue timing will be highly binary
The SOW with Eureka includes non-refundable milestone fees, creating accrued liabilities as dosing milestones are achieved.
Impact: Affects R&D expense and accrued liabilities
Option grants under the incentive plan create non-cash compensation expense that can rise with equity awards.
Impact: Impacts operating loss and equity dilution analysis
The company evaluates certain financing instruments for derivative treatment under ASC 815, which can introduce mark-to-market volatility.
Impact: Can affect earnings and balance-sheet volatility
The business combination was accounted for as a reverse recapitalization, affecting historical comparability and equity presentation.
Impact: Limits comparability with pre-combination periods
Similar listed companies
Publicly listed companies with a comparable business focus.
Ernexa Therapeutics Inc.
ERNAW · Pharmaceutical Preparations
Cue Biopharma, Inc.
CUE · Pharmaceutical Preparations
Cue Biopharma is a clinical-stage biopharmaceutical company developing injectable precision immunotherapies designed to selectively modulate disease-relevant T cells.
Immatics N.V.
IMTX · Biological Products, (No Diagnostic Substances)
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
IO Biotech, Inc.
IOBTQ · Pharmaceutical Preparations
Equillium, Inc.
EQ · Pharmaceutical Preparations
Last updated: 24/09/2026